Abstract 23
Progress in lymphatic vessel biology and novel imaging techniques have established the importance 24 of lymphatic vasculature as part of the cardiovascular system. Lymphatic vessel network regulates 25 many physiological processes important in the heart such as fluid balance, transport of extravasated 26 proteins and trafficking of immune cells. Therefore, lymphangiogenic therapy could be beneficial in 27 the treatment of cardiovascular diseases, for example by improving reverse cholesterol transport from 28 atherosclerotic lesions or resolving edema and fibrosis after myocardial infarction. In this review, we 29 first describe recent findings in the development and function of cardiac lymphatic vessels and 30 subsequently focus on the prospects of pro-and anti-lymphangiogenic therapies in cardiovascular 31 diseases. 32 33 34 the cleavage of pro-VEGF-C to its active form by ADAM Metallopeptidase With Thrombospondin 109 Type 1 Motif 3 (ADAMTS3) metalloproteinase [28] . In a recent study, Bui et al. [29] confirmed that a 110 complex of CCBE1-ADAMTS3 is required for proper proteolytic activation of VEGF-C but not 111 VEGF-D. It was spe culated that VEGF-C is re quired for the growth of developing lymphatics 112 whereas VEGF-D serves as a growth factor for reactive, local lymphatic growth during inflammatory 113 reactions in adults [29] . In addition to CCBE1, neuropilin 2 (NRP2) can enhance VEGFR-3 signaling 114
by interacting with VEGFR-3 and thereby increasing the affinity of LECs towards VEGF-C [30] . 115
Podoplanin 117
The expression of a transmembrane O-glycoprotein podoplanin (PDPN) distinguishes endothelial 118 cells inside the embryonic veins from fully budded LECs [31] . Studies in Pdpn -/-mice have suggested 119 that the expression of PDPN is required for platelet activation and aggregation by binding to a platelet 120 factor C-type lectin-like receptor 2 (CLEC-2). Platelets without PDPN function cannot aggregate and 121 therefore PDPN knockout embryos have incomplete lymphovenous separation and blood-filled 122 lymphatics [32, 33] . PDPN expression is sustained in mature LECs and it is widely used as a LEC 123 marker [5] . 124
In the adult heart, the cardiac lymphatic system forms a network of capillaries and precollecting 146 lymphatic vessels that are located most abundantly in the ventricles. The human left ventricular wall 147 possesses approximately 30 lymphatic vessels/mm2, significantly less than blood capillaries [39, 40] . 148
There is some species-specific variation in the anatomy of cardiac lymphatics. For example, the 149 majority of lymphatics in rabbit and mouse hearts are located in the subepicardium and outer 150 myocardium, whereas in humans lymphatic capillaries can be visualized evenly in the myocardial, 151 subepicardial, and subendocardial areas (reviewed by Ratajska [40] ). Cardiac lymphatic flow begins 152 from the subendocardium, runs through the myocardium and enters into the capillary lymphatic 153 plexus in the epicardium [41] . The diameter of the capillaries varies, depending on the species and 154 study, from 20 µm up to 400 µm [40] . Lymphatic capillaries converge into large valve-containing 155 collecting lymphatics that run along the left conal and left cardiac veins, and finally drain into 156 subaortic and paratracheal lymph nodes [37] . All cardiac valves also possess lymphatics, that are 157 mainly located in the basal part but also some are scattered peripherally [39] . 158
159
Many congenital lymphatic disorders cause lymphatic dysfunction and lymphedema primarily in the 160 legs and feet of the individual but not in the heart, such as Milroy's disease, associated with missense 161 mutations in VEGFR-3 tyrosine kinase domain [42] and lymphedema-distichiasis syndrome, caused 162 by mutations in the FOXC2 gene [43] . However, Noonan syndrome, affected by the upregulated 163 RAS-MAPK signaling, is associated with several signs of lymphatic dysfunction such as 164 lymphedema, lymphatic dysplasias, chylous reflux and intestinal lymphangiectasis, but also 165 congenital heart defects characterized by pulmonary valve stenosis, atrial septal defects and 166 hypertrophic cardiomyopathy [44] . Cardiac lymphatic anatomy or function has not been recorded in 167 these patients, but lymphatic dysfunction might affect the progression of heart defects as the 168 development of lymphatics is abnormal. 169
170
In addition to hereditable lymphatic dysfunctions, lymphatic vessels play a role in several heart-171 related conditions and might have a therapeutical potential. These will be discussed in the further 172 sections of the review. lymphatics are also present in human coronary arteries as well as in atherosclerotic plaques. 234
Lymphatics were found in intima, media and adventitia of the arterial wall, and moreover, increased 235 medial lymphangiogenesis was present in progressive atherosclerotic lesions, which could be a natural 236 response to resolve increased inflammation and cholesterol build up [39] . Interestingly, it has been 237 shown that ApoA1 and HDL concentration in human artery wall is as high as in the plasma, thus 238 emphasizing a potential role of arterial lymphatics in carrying excess cholesterol out from 239 atherosclerotic plaques [53] . 240
241
As mentioned earlier, the mechanism for HDL transport from peripheral tissue to the circulation has 242 remained unknown. Recently, it was suggested that Scavenger receptor class B member 1 (SR-BI) is 243 expressed in the lymphatic endothelium where it mediates the internalization and transport of HDL. 244
Furthermore, downregulation of SR-BI by small interfering RNAs resulted in 80% inhibition of HDL 245 uptake by LECs in vitro. It was also shown that treatment of wild type mice with an SR-BI blocking 246 antibody inhibits the transport of HDL via lymphatics by 75%. This is the first study demonstrating 247 that lymphatics can actively transport HDL cholesterol via SR-BI dependent mechanism [50] . 248
249
All aforementioned studies show that functional lymphatic vasculature is responsible for cholesterol 250 r e m o v a l f r o m t h e a r t e r y w a l l a n d t h e r e f o r e , i n f l u e n c e s t h e a t h e r o s c l e r o t i c p l a q u e f o r m a t i o n . 251
Additionally, it has been proposed that HDL enters the lymphatic vasculature via SR-BI dependent 252 mechanism before reaching the bloodstream. These results suggest that therapies aimed at reducing 253 atherosclerosis by way of induced lymphangiogenesis and enhanced HDL transport may be beneficial. 254
Thus far, clinical trials aiming to increase HDL levels have failed to reduce the risk of recurrent 255 cardiovascular events [54, 55] . This accentuates that simply increasing the HDL levels is not a 256 sufficient treatment, thus targeting the mechanisms behind HDL transport could provide a better 257 therapeutic outcome. 258
Myocardial infarction 260
As in other parts of the body, cardiac lymphatic vessels are required for the maintenance of fluid 261 balance and immune surveillance, both important factors during and after MI. Briefly, MI is primarily 262 a manifestation of coronary artery disease where a part of the heart muscle is damaged by a blockage 263 in blood flow. In most cases, the rupture of the atherosclerotic plaques in the coronary artery wall lead 264 in an MI rat model. While, no effect was seen in infarct scar size, cardiac hypertrophy was decreased. 283
In addition, precollector remodeling was attenuated and fluid balance was improved. Both VEGF-C 284 and VEGF-D therapy has been shown to promote blood flow and healing in the rabbit and mouse hind 285 limb after ischemia, but the role of lymphangiogenesis in these studies remains questionable [60] [61] [62] [63] . 286
In addition, gene therapy trial in humans showed beneficial effects of VEGF-C therapy on angina 287 score [64, 65]. Unfortunately, lymphangiogenesis was not analyzed in these studies. 288
289

Diseases of heart valves 290
Lymphatic vessels have been shown to be present both in normal and diseased human heart valves. 291
As compared to blood vessels, lymphatic vasculature is proportionately more prominent in valves 292 t h a n i n t h e o t h e r a r e a s o f t h e h e a r t [ 3 9 ] . A f e w p u b l i c a t i o n s h a v e r e p o r t e d t h a t i n c r e a s e d 293
lymphangiogenesis is observed during valve pathologies [39, 66, 67]. Human heart valve endocarditis 294 is characterized by inflammation and abnormal growth, as well as inflammation-associated 295 lymphangiogenesis. Lymphatic vasculature within the diseased heart valves was shown to be 296 increased, both in vessel size and density [67] . However, it is not clear whether lymphangiogenesis 297 within the valves is enough to resolve the inflammation and would lymphangiogenic therapy be a 298 sufficient treatment. 
320
A r e c e n t s t u d y d e m o n s t r a t e d t h a t c a r d i a c a l l o g r a f t i s c h e m i a-r e pe r f u s i o n i n j u r y i n t h e r a t h e a r t 321
increased graft VEGF-C expression and lymphatic vessel activation. Treatment with a VEGFR-3 322 inhibitor led to reduced lymphatic vessel activation and dendritic cell maturation, subsequently 323 reducing chronic inflammation and resulting in attenuated acute and chronic rejection. Furthermore, 324 mouse studies using transplanted hearts carrying a LEC specific VEGFR-3 deletion confirmed the 325 previous results that VEGFR-3 inhibition leads to prolonged cardiac allograft survival [69] .inhibitors directly to the transplanted mouse heart. These microparticles mimic lymphocyte migration 330 to the lymph nodes and therefore target the activation of the adaptive immunity. Microparticles 331 delivered to draining lymph nodes successfully prolonged heart allograft survival [70] . 332 333
From mice to humans? 334 335
Most of the successful cardiac studies within the lymphatic field have utilized rodent models (see 336   Table 1 ), which leads us to question whether the methods and results from the small animal studies 337 can be translated to complex and chronic human diseases. To resolve this question, the next important 338 step is large animal studies. There are only a few publications utilizing pig models, which demonstrate 339 that lymphedema can be treated with local injections of adenoviruses encoding lymphangiogenic 340
VEGF-C [71-73], VEGF-C156S [ 7 2 ] o r V E G F -D [ 7 3 ] . T h e s a m e t r e a t m e n t s t r a t e g i e s c o u l d b e 341
employed to treat cardiac pathologies in large animal models. There is an ongoing clinical trial for 342 enhancing cardiac angiogenesis, which emphasizes that the methods to treat MI patients are already 343 What is the most applicable delivery route and method for lymphangiogenic therapy for 488 myocardial ischemia? 489
Could attenuation of lymphatic vessel activation through VEGFR-3 inhibition therapy be 490 employed in the clinics to treat heart transplantation patients to prolong cardiac allograft 491
survival? 492
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